PubMed=8741612; DOI=10.1292/jvms.58.469
Nakaichi M., Taura Y., Kanki M., Mamba K., Momoi Y., Tsujimoto H., Nakama S.
Establishment and characterization of a new canine B-cell leukemia cell line.
J. Vet. Med. Sci. 58:469-471(1996)

PubMed=22236332; DOI=10.1111/j.1476-5829.2011.00299.x
Seiser E.L., Thomas R., Richards K.L., Kelley M.K., Moore P., Suter S.E., Breen M.
Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines.
Vet. Comp. Oncol. 11:30-50(2013)

PubMed=23363222; DOI=10.1111/jvp.12039
Zandvliet M., Teske E., Chapuis T., Fink-Gremmels J., Schrickx J.A.
Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
J. Vet. Pharmacol. Ther. 36:583-587(2013)

PubMed=23365669; DOI=10.1371/journal.pone.0054464; PMCID=PMC3554772
Wells J.W., Evans C.H., Scott M.C., Rutgen B.C., O'Brien T.D., Modiano J.F., Cvetkovic G., Tepic S.
Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation.
PLoS ONE 8:e54464.1-e54464.9(2013)

PubMed=24975508; DOI=10.1016/j.tiv.2014.06.004
Zandvliet M., Teske E., Schrickx J.A.
Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma.
Toxicol. In Vitro 28:1498-1506(2014)

PubMed=29674676; DOI=10.1038/s41598-018-23207-7; PMCID=PMC5908872
Taher L., Beck J., Liu W., Roolf C., Soller J.T., Rutgen B.C., Hammer S.E., Chodisetti M., Sender S., Sterenczak K.A., Fuellen G., Junghanss C., Brenig B., Nolte I., Schutz E., Murua Escobar H.
Comparative high-resolution transcriptome sequencing of lymphoma cell lines and de novo lymphomas reveals cell-line-specific pathway dysregulation.
Sci. Rep. 8:6279-6279(2018)